Markets:

Overview

News

Currencies

International

Treasuries

Mersana Therapeutics, Inc. - Common Stock (NQ:MRSN)

28.59 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mersana Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Myovant Sciences And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

October 24, 2022

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday ↗

October 06, 2022

Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday.

Via Benzinga

Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy ↗

August 09, 2022

Via Benzinga

Recap: Mersana Therapeutics Q1 Earnings ↗

May 09, 2022

Mersana Therapeutics (NASDAQ:MRSN) reported its Q1 earnings results on Monday, May 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary ↗

September 12, 2022

Via Benzinga

Mersana Shares Climb As FDA Grants Fast Track Status To Triple-Negative Breast Cancer Candidate ↗

September 12, 2022

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ: MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or...

Via Benzinga

Mersana Therapeutics's Return On Capital Employed Insights ↗

September 01, 2022

Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $4.28 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 10.5%, resulting in a loss of $52.22...

Via Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 16, 2022

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 09, 2022

Via Benzinga

Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday ↗

August 10, 2022

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.

Via Benzinga

Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session ↗

August 09, 2022

Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD....

Via Benzinga

Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2 ↗

August 09, 2022

U.S. stocks traded mixed this morning, with the Nasdaq dropping around 90 points on Tuesday.

Via Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 09, 2022

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 08, 2022

Via Benzinga

Earnings Scheduled For August 8, 2022 ↗

August 08, 2022

Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.

Via Benzinga

Earnings Preview For Mersana Therapeutics ↗

August 05, 2022

Mersana Therapeutics (NASDAQ:MRSN) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that Mersana...

Via Benzinga

89 Biggest Movers From Friday ↗

June 21, 2022

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

Mersana Therapeutics's Return On Capital Employed Overview ↗

June 03, 2022

According to Benzinga Pro data, during Q1, Mersana Therapeutics (NASDAQ:MRSN) posted sales of $2.04 million. Earnings were up 3.52%, but Mersana Therapeutics still reported an overall loss of $47.26...

Via Benzinga

Executives Buy Around $17M Of 5 Penny Stocks ↗

May 19, 2022

The Nasdaq Composite index tumbled by more than 550 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their...

Via Benzinga

Mersana Stock Gains On FDA Orphan Drug Designation For Gastric Cancer Drug ↗

May 19, 2022

Mersana Therapeutics, Inc. (NASDAQ: MRSN) received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its drug candidate XMT-2056 or the treatment of gastric cancer. The...

Via Benzinga

The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate ↗

May 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

34 Stocks Moving In Monday's Mid-Day Session ↗

April 18, 2022

Gainers Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions....

Via Benzinga

Earnings Scheduled For May 9, 2022 ↗

May 09, 2022

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

Via Benzinga

68 Biggest Movers From Yesterday ↗

April 19, 2022

Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More ↗

April 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 23, 2022

Gainers Creative Medical Tech (NASDAQ:CELZ) shares rose 78.8% to $3.04 during Wednesday's pre-market session. The market value of their outstanding shares is at $19.2...

Via Benzinga

Looking Into Mersana Therapeutics's Return On Capital Employed ↗

March 01, 2022

Mersana Therapeutics (NASDAQ:MRSN) brought in sales totaling $11.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 7.72%, resulting in...

Via Benzinga

Recap: Mersana Therapeutics Q4 Earnings ↗

February 28, 2022

Mersana Therapeutics (NASDAQ:MRSN) reported its Q4 earnings results on Monday, February 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Mersana Therapeutics, Inc. - Common Stock (NQ:MRSN)

All News about Mersana Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today